Familial Cancer Registry Shared Resource - Claudine Isaacs, MD The Familial Cancer Registry (FCR) Shared Resource is a unique shared resource that provides investigators access to one of the nation s largest collections of individuals from high-risk breast cancer families. The FCR is a comprehensive resource that includes detailed demographic data, family history information, medical history, cancer risk factors, tissue from surgeries (benign and malignant), immortalized lymphocytes, red blood cells, buffy coat, plasma, blood clot and serum, all of which can be linked confidentially to the results of genetic testing. The FCR has existed since 1998. In 2001 the FCR received developmental funds from the Cancer Center Support Grant of the Lombardi Comprehensive Cancer Center (Lombardi) to become a shared resource. Currently, 2,143 subjects are enrolled in the FCR, representing an increase of 1,119 individuals since the last grant submission. The FCR aims to provide interested investigators with high-quality data and biospecimens from a genetically characterized population that is at high risk of developing certain types of cancer. The FCR resources have supported important research in three Lombardi programs. Research topics have ranged from behavioral research (e.g., how genetic testing affects medical decision-making) to basic science (e.g., examining DNA repair gene polymorphisms in hereditary breast cancer). Fifty publications were supported by the FCR from 2003 through 2008. New developments in the FCR since the last application include the creation of tissue microarrays of breast tumors from women with a hereditary predisposition to this disease, the expansion of the FCR to recruit from another MedStar Hospital (Washington Hospital Center), and the recruitment of individuals with hereditary predisposition to colorectal cancer. Claudine Isaacs, MD, directs the FCR, is the Medical Director of the Cancer Assessment and Risk Evaluation (CARE) program, and is the codirector of the Fisher Center for Familial Cancer Research. Dr. Isaacs is an expert in the genetic factors that predispose to breast and other cancers. Her clinical interest also includes the treatment of patients with breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA051008-18
Application #
8256573
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-05-01
Budget End
2012-04-30
Support Year
18
Fiscal Year
2011
Total Cost
$18,734
Indirect Cost
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Laiakis, Evagelia C; Mak, Tytus D; Strawn, Steven J et al. (2018) Global metabolomic responses in urine from atm deficient mice in response to LD50/30 gamma irradiation doses. Environ Mol Mutagen 59:576-585
O'Neill, Suzanne C; Taylor, Kathryn L; Clapp, Jonathan et al. (2018) Multilevel Influences on Patient-Oncologist Communication about Genomic Test Results: Oncologist Perspectives. J Health Commun 23:679-686
Kim, Sang-Soo; Harford, Joe B; Moghe, Manish et al. (2018) Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Nucleic Acids Res 46:1424-1440
Wallington, Sherrie; Oppong, Bridget; Dash, Chiranjeev et al. (2018) A Community-Based Outreach Navigator Approach to Establishing Partnerships for a Safety Net Mammography Screening Center. J Cancer Educ 33:782-787
Wärri, Anni; Cook, Katherine L; Hu, Rong et al. (2018) Autophagy and unfolded protein response (UPR) regulate mammary gland involution by restraining apoptosis-driven irreversible changes. Cell Death Discov 4:40
Pohlmann, Paula R; Isaacs, Claudine (2018) Extended Adjuvant Endocrine Therapy for Postmenopausal Women: Treating Many to Benefit a Few. J Natl Cancer Inst 110:
Fu, Ying; Silverstein, Shana; McCutcheon, Justine N et al. (2018) An endogenous DNA adduct as a prognostic biomarker for hepatocarcinogenesis and its prevention by Theaphenon E in mice. Hepatology 67:159-170
Stires, Hillary; Heckler, Mary M; Fu, Xiaoyong et al. (2018) Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities. Mol Cell Endocrinol 471:105-117
Xiao, David; Zheng, Chaoyi; Jindal, Manila et al. (2018) Medicaid Expansion and Disparity Reduction in Surgical Cancer Care at High-Quality Hospitals. J Am Coll Surg 226:22-29
Kozlik, Petr; Goldman, Radoslav; Sanda, Miloslav (2018) Hydrophilic interaction liquid chromatography in the separation of glycopeptides and their isomers. Anal Bioanal Chem 410:5001-5008

Showing the most recent 10 out of 1120 publications